Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01201811
First received: September 13, 2010
Last updated: June 25, 2014
Last verified: June 2014

September 13, 2010
June 25, 2014
November 2010
May 2013   (final data collection date for primary outcome measure)
  • Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator [ Time Frame: Response assessed at end of cycle 6; through week 24; End of study ] [ Designated as safety issue: No ]

    Hematologic Response according to the 2000 International Working Group (IWG) response criteria for MDS was based on the Investigators determination and defined as:

    • Complete Response (CR): repeat bone marrow (BM) shows <5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (>110 g/L), neutrophils (≥1.5x10^9/L), platelets (≥100x10^9/L), blasts (0%) and no dysplasia
    • Partial Response (PR): same as CR for peripheral blood: BM shows blasts decrease by ≥ 50% or a less advanced FAB classification from pretreatment
    • Stable disease (SD): failure to achieve a PR, no evidence of progression for at least 2 months.
    • Failure: death during treatment or disease progression
    • Relapse After CR or PR: return to pretreatment BM blast percent or decrement of ≥ 50% from remission/response levels in granulocytes or platelets; or reduction in hgb by ≥20 g/L or transfusion dependence
    • Disease Progression: change in blast levels
    • Disease Transformation to AML
  • Percentage of Participants Showing Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Sponsor [ Time Frame: Response assessed at end of cycle 6; through week 24; End of study ] [ Designated as safety issue: No ]

    Hematologic improvements (HI) have 4 categories:

    1. Erythroid response (HI-E): Major >20g/L increase or transfusion independent. Minor- 10-20g/L increase or ≥50% decrease in transfusion requirements.
    2. Platelet response (HI-P): Major absolute increase of ≥30x10^9/L or platelet transfusion independence. Minor-≥50% increase.
    3. Neutrophil response (HI-N): Major 100% increase or an absolute increase of >0.5x10^9/L. Minor-≥100% increase and absolute increase of <0.5x10^9/L
    4. Progression or relapse after HI

    Overall hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin <100g/L or RBC transfusion-dependent, platelet count <100x10^9/L or platelet transfusion dependent, absolute neutrophil count <1.5x10^9/L. Sponsor's determination was derived using clinically relevant data.

    Denominator for progression/relapse after HI included participants who had achieved HI.

Proportion of participants with a hematologic response (defined as Complete Response and Partial Response), and Hematologic Improvement based on International Working Group 2000 response criteria for Myelodysplastic Syndromes. [ Time Frame: 7 months ] [ Designated as safety issue: No ]
Proportion of participants with a hematologic response (defined as Complete Response and Partial Response), and Hematologic Improvement based on International Working Group 2000 response criteria for Myelodysplastic Syndromes.
Complete list of historical versions of study NCT01201811 on ClinicalTrials.gov Archive Site
  • Number of Red Blood Cell (RBC) Transfusions by Cycle [ Time Frame: Up to week 24;The on-treatment period was considered the period from the date of the first dose to the last treatment study visit. ] [ Designated as safety issue: No ]
    The number of transfusions received 56 days prior to treatment and during study were standardized per 28 days and summarized by cycle for RBCs. The formula for standardizing per 28 days was: [(# of transfusions in the measurement period / length of the measurement period (days)) x 28], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of RBC transfusions per cycle.
  • Number of Platelet Transfusions by Cycle [ Time Frame: Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit. ] [ Designated as safety issue: No ]
    The number of transfusions received 56 days prior to treatment and during study was standardized per 28 days and summarized by cycle for platelets. The formula for standardizing per 28 days was: [(# of transfusions in the measurement period / length of the measurement period (days)) x 28], where the measurement period was either baseline or the relevant cycle length. For each participant the overall post-baseline average was calculated as the average of # of platelet transfusions per cycle.
  • Number of Infections (Post-baseline Average) Requiring Intravenous Antibiotics, Anti-fungals, or Antivirals Per 28 Days [ Time Frame: Up to week 24; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit. ] [ Designated as safety issue: No ]
    The on-treatment adverse event of infection requiring IV antibiotics, antifungals, or antivirals per 28 days/cycle. The overall post-baseline average is the average of number of infections requiring IV antibiotics or IV antiviral per 28 days/cycle. For each participant the overall post-baseline average was calculated as the average of # of infections requiring IV antibiotics or IV antiviral per 28 days per cycle.
  • Number of Participants With Adverse Events (AE) [ Time Frame: From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study drug 244 days) ] [ Designated as safety issue: Yes ]

    An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE):

    • Death;
    • Life-threatening event;
    • Any inpatient hospitalization or prolongation of existing hospitalization;
    • Persistent or significant disability or incapacity;
    • Congenital anomaly or birth defect;
    • Any other important medical event.

    The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Treatment Emergent AEs (TEAE) were defined as AEs with an onset date on or after the first dose of study drug and within 28 days after the date of the last dose. In addition, any AE that occurred beyond this timeframe and that was assessed by the investigator as possibly related to study drug was considered a TEAE.

  • Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Azacitidine [ Time Frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    Area under the plasma concentration-time curve from time zero to infinity (AUC∞) following multiple doses of Azacitidine on Day 7; if possible, the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC∞ = AUCt + (Ct/ λz ), where Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz. If % AUC extrapolated is ≥ 25%, AUC∞ was not reported.
  • Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Azacitidine [ Time Frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.
  • Maximum Observed Plasma Concentration (Cmax) of Azacitidine [ Time Frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    The observed maximum plasma concentration obtained directly from the observed concentration versus time data.
  • Time to Maximum Plasma Concentration (Tmax) of Azacitidine [ Time Frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    Time to maximum observed plasma concentration obtained directly from the observed concentration versus time data.
  • Terminal Phase of Half-life (T1/2) of Azacitidine [ Time Frame: Timeframe: Day 7 pre-dose at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    The apparent terminal half-life was calculated according to the following equation t½ = 0.693/λz.
  • Apparent Total Plasma Clearance (CL/F) of Azacitidine [ Time Frame: Timeframe: Days 5 and 6 at predose and Day 7 (pre-dose) at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    Apparent total plasma clearance (CL/F) of Azacitidine was calculated as Dose/AUC∞
  • Apparent Volume of Distribution (Vd/F) of Azacitidine [ Time Frame: Timeframe: Day 7 pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8 hours post-dose ] [ Designated as safety issue: No ]
    Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/λz
  • Number of red blood cell transfusions [ Time Frame: 7 months ] [ Designated as safety issue: No ]
  • Number of platelet transfusions [ Time Frame: 7 months ] [ Designated as safety issue: No ]
  • Number of infections requiring intravenous antibiotics [ Time Frame: 7 months ] [ Designated as safety issue: No ]
  • Safety (type, frequency, severity, and relationship of adverse events to azacitidine) [ Time Frame: 7 months ] [ Designated as safety issue: Yes ]
  • Steady-state plasma azacitidine concentrations [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Dependent at Baseline [ Time Frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit ] [ Designated as safety issue: No ]

    A participant was considered transfusion dependent at baseline if the participant had one or more Red Blood Cell transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no transfusions during any 56 consecutive days or more (e.g., Day 1 through 56, Day 2 through 57, etc). Otherwise, they were considered transfusion dependent.

    The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)

  • Participants' Red Blood Cell (RBC) Transfusion Status for Participants Who Were Transfusion Independent at Baseline [ Time Frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit. ] [ Designated as safety issue: No ]

    A participant was considered RBC transfusion-independent at baseline if the participant had no RBC transfusions during the 56 days prior to first dose. During the study, a participant was considered transfusion independent during the on-treatment period if the participant had no RBC transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered transfusion dependent.

    The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: RBC dependent at BL=32, RBC independent at BL=12)

  • Participants' Platelet Transfusion Status for Participants Who Were Transfusion Dependent at Baseline [ Time Frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit. ] [ Designated as safety issue: No ]

    A participant was considered platelet transfusion dependent at baseline if the participant had one or more platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent.

    The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)

  • Participants' Platelet Transfusion Status for Participants Who Were Transfusion Independent at Baseline [ Time Frame: Baseline to Cycle 6; The on-treatment period was considered the period from the date of the first dose to the last treatment study visit. ] [ Designated as safety issue: No ]

    A participant was considered platelet transfusion independent at baseline if the participant had no platelet transfusions during the 56 days prior to first dose. During the study, a participant was considered platelet transfusion independent during the on-treatment period if the participant had no platelet transfusions during any 56 consecutive days or more (eg, Days 1 through 56, Days 2 through 57, etc.). Otherwise, they were considered platelet transfusion dependent.

    The total N=44, but 1 participant can only be dependent or independent at baseline for each type of transfusion (ie, total = 44: platelet dependent at BL=18, platelet independent at BL=26)

Not Provided
 
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.

The primary purpose of this study is to determine the effectiveness and safety of azacitidine in the treatment of Taiwanese subjects with higher-risk Myelodysplastic Syndrome (MDS).

The study has 3 phases which include the Screening Phase, the Treatment Phase, and the Post-Treatment Phase and outlined as follows:

Screening Phase:

Participants will provide informed consent prior to undergoing any study-related procedures. Screening procedures are to take place within 28 days prior to the initiation of azacitidine treatment (Day 1, Cycle 1). Subject eligibility will be based on central pathology review. Bone marrow aspirate and bone marrow biopsy will be collected at screening and sent for morphological assessment by a central pathology reviewer prior to the subject receiving investigational product (IP). The central pathology reviewer will document the MDS classification according to the French-American-British (FAB) and World Health Organization (WHO) criteria.

A standard cytogenetic metaphase preparation will be prepared from the bone marrow aspirate and sent to the local or central laboratory (for sites without local analysis capability) for the cytogenetic analysis prior to receiving IP.

The IPSS score will be calculated using the central reviewer's pathology report for bone marrow blast percentage, local cytogenetic assessment for karyotype, and central laboratory report for number of cytopenias.

Treatment Phase:

The first dose of azacitidine for each participant begins on Day 1 of Cycle 1. All participants will receive azacitidine 75 mg/m^2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from treatment. Visits during the treatment phase are to be scheduled weekly for the first 2 cycles, then every other week for all subsequent cycles throughout the rest of the study. Safety and efficacy measures are to be performed weekly, every other week, every 4 weeks, or at 24 weeks, depending on the procedure.

Post-Treatment Phase:

All discontinued participants, regardless of reason for discontinuation, should undergo end-of-study procedures at the time of study discontinuation. Participants will have a follow-up visit for the collection of adverse events up to 28 days after last IP dose.

Interventional
Phase 4
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Myelodysplastic Syndromes
Drug: Azacitidine
Participants received azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days for up to 6 cycles, unless they discontinued from the treatment. In addition, participants may have received best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
Experimental: Single-Arm
Azacitidine 75 mg/m^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
Intervention: Drug: Azacitidine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • A diagnosis of Refractory anemia with excess blasts (RAEB) or Refractory anemia in transformation (RAEB-T) according to French-American-British (FAB) classification for Myelodysplastic Syndrome (MDS) and with an International Prognostic Scoring System (IPSS) score of intermediate-2 or high risk or a diagnosis of myelodysplastic Chronic myelomonocytic leukemia (CMML) per modified FAB criteria.
  • Taiwanese males and females ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2;
  • Adequate hepatic and renal organ function

Exclusion Criteria:

  • Previous treatment with azacitidine or decitabine
  • Malignant disease diagnosed within prior 12 months
  • Uncorrected red cell folate deficiency or vitamin B12 deficiency
  • Diagnosis of metastatic disease
  • Malignant hepatic tumors
  • Known or suspected hypersensitivity to azacitidine or mannitol
  • Prior transplantation or cytotoxic therapy, including azacitidine and chemotherapy, administered to treat MDS
  • Treatment with erythropoietin or myeloid growth factors during the 21 days prior to Day 1 of Cycle 1 or androgenic hormones during the 14 days prior to Day 1 of Cycle 1;
  • Active Human immunodeficiency virus (HIV) or viral hepatitis type B or C
  • Treatment with other investigational drugs within the previous 30 days prior to Day 1 of Cycle 1, or ongoing adverse events from previous treatment with investigational drugs, regardless of the time period;
  • Pregnant or lactating females
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT01201811
AZA-MDS-001
No
Celgene Corporation
Celgene Corporation
Not Provided
Study Director: C L Beach, PharmD Celgene Corporation
Celgene Corporation
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP